Research Results
⁍ Balancing the beautiful and the good in pursuit of biomarkers for depression
⁍ The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder
⁍ Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis
⁍ Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study
⁍ The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis
⁍ Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression
⁍ Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder
⁍ Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence
⁍ Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder
⁍ Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein
⁍ Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression
⁍ Recovery and subsequent recurrence in patients with recurrent major depressive disorder
⁍ Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder
⁍ Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
⁍ How Shall I Diagnose Thee? Let Me Count the Ways
⁍ Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression
⁍ Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression
⁍ Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis
⁍ Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse
⁍ The role of dopamine in the pathophysiology of depression
⁍ Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence
⁍ Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy
⁍ Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
⁍ Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges
⁍ Neuroimaging Advances for Depression
⁍ Toward a neuroimaging treatment selection biomarker for major depressive disorder
⁍ AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale
⁍ Neuroimaging-based biomarkers for treatment selection in major depressive disorder
⁍ Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression
⁍ Spiritual health practitioners' contributions to psychedelic assisted therapy: A qualitative analysis
⁍ Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
⁍ Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies
⁍ Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse.
⁍ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
⁍ Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)
⁍ Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
⁍ Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids
⁍ Metabolomic and inflammatory signatures of symptom dimensions in major depression.
⁍ Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
⁍ Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
⁍ Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
⁍ Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
⁍ Review of nutritional supplements for the treatment of bipolar depression
⁍ Balancing the beautiful and the good in pursuit of biomarkers for depression
⁍ The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder
⁍ Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis
⁍ Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study
⁍ The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis
⁍ Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression
⁍ Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder
⁍ Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence
⁍ Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder
⁍ Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein
⁍ Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression
⁍ Recovery and subsequent recurrence in patients with recurrent major depressive disorder
⁍ Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder
⁍ Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
⁍ How Shall I Diagnose Thee? Let Me Count the Ways
⁍ Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression
⁍ Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression
⁍ Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis
⁍ Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse
⁍ The role of dopamine in the pathophysiology of depression
⁍ Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence
⁍ Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy
⁍ Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
⁍ Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges
⁍ Neuroimaging Advances for Depression
⁍ Toward a neuroimaging treatment selection biomarker for major depressive disorder
⁍ AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale
⁍ Neuroimaging-based biomarkers for treatment selection in major depressive disorder
⁍ Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression
⁍ Spiritual health practitioners' contributions to psychedelic assisted therapy: A qualitative analysis
⁍ Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
⁍ Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies
⁍ Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse.
⁍ Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
⁍ Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)
⁍ Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature
⁍ Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids
⁍ Metabolomic and inflammatory signatures of symptom dimensions in major depression.
⁍ Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
⁍ Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
⁍ Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
⁍ Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
⁍ Review of nutritional supplements for the treatment of bipolar depression
To find out about actively recruiting studies and how you can participate in them